<DOC>
	<DOCNO>NCT00068666</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , temozolomide , use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining temozolomide radiation therapy may make tumor cell sensitive radiation therapy kill tumor cell . PURPOSE : This phase II trial study well give temozolomide together radiation therapy work treat patient stage IV malignant melanoma measurable unresectable cancer limited central nervous system .</brief_summary>
	<brief_title>Temozolomide Radiation Therapy Treating Patients With Stage IV Malignant Melanoma With Measurable Unresectable Cancer Central Nervous System</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate patient stage IV malignant melanoma measurable unresectable disease central nervous system treat temozolomide radiotherapy . Secondary - Determine safety regimen patient . - Determine survival patient treat regimen . - Determine effect regimen performance status mental status patient . - Determine response extra-cranial disease patient treat regimen . OUTLINE : Patients receive concurrent chemoradiotherapy comprise whole brain radiotherapy daily day 1-5 , 8-13 , 16-21 oral temozolomide daily day 1-5 . Subsequent treatment temozolomide repeat every 4 week 8 course absence disease progression unacceptable toxicity . Patients follow every 2 month . PROJECTED ACCRUAL : A total 18-41 patient accrue study within 13-30 month .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IV malignant melanoma measurable unresectable disease limited central nervous system ( CNS ) Study entry within 14 day diagnosis brain metastasis Recursive partition analysis class I II Disease know standard therapy exist potentially curative proven capable extend life expectancy No meningeal carcinomatosis base image study positive result CSF analysis No evidence metastatic disease outside CNS PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 70100 % Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9.0 g/dL Hepatic AST great 3 time upper limit normal ( ULN ) Alkaline phosphatase great 3 time ULN Renal Creatinine great 1.5 time ULN Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent uncontrolled infection No malignancy within past 5 year except basal cell squamous cell skin cancer treat local resection No prior allergy intolerance dacarbazine No hypersensitivity temozolomide component PRIOR CONCURRENT THERAPY : Biologic therapy More 4 week since prior biologic therapy More 4 week since prior immunotherapy Chemotherapy No prior temozolomide More 4 week since prior chemotherapy ( 6 week mitomycin nitrosoureas ) recover Endocrine therapy Concurrent steroid allow dose stable least 7 day prior CNS image Radiotherapy More 4 week since prior radiotherapy No prior radiotherapy 15 % bone marrow No prior radiotherapy head neck area No prior radiosurgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>tumor metastatic brain</keyword>
</DOC>